IQ EQ FUND MANAGEMENT IRELAND Ltd Sells 5,104 Shares of Zoetis Inc. $ZTS

IQ EQ FUND MANAGEMENT IRELAND Ltd trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 56.5% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 3,926 shares of the company’s stock after selling 5,104 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Zoetis were worth $574,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of ZTS. Brighton Jones LLC lifted its holdings in Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after acquiring an additional 2,978 shares during the period. Empowered Funds LLC lifted its stake in shares of Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares during the period. Intech Investment Management LLC boosted its holdings in shares of Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after buying an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC grew its position in Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after buying an additional 1,422 shares during the period. Finally, Callan Family Office LLC grew its position in Zoetis by 140.1% during the second quarter. Callan Family Office LLC now owns 15,717 shares of the company’s stock valued at $2,451,000 after buying an additional 9,170 shares during the period. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. UBS Group set a $136.00 price target on shares of Zoetis in a research note on Thursday, January 29th. BTIG Research reiterated a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Wednesday, December 3rd. Bank of America lowered Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price target for the company. in a report on Monday, December 15th. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price objective (down previously from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Finally, The Goldman Sachs Group raised Zoetis to a “buy” rating in a research report on Monday, December 15th. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $152.45.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Pelican Bay Capital Management increased its stake and is betting on Zoetis to benefit from the expanding pet care market — a vote of confidence from an institutional investor that can support the stock. Pelican Bay Capital Management Bets on Zoetis (ZTS) to Capitalize on Expanding Pet Care Market
• Positive Sentiment: The board declared a second‑quarter cash dividend of $0.53 per share (annualized yield ~1.7%; ex‑dividend Apr 20, payable Jun 2). The payout supports income investors and signals steady free cash flow. Zoetis Declares Second Quarter 2026 Dividend
• Positive Sentiment: Analyst coverage from Zacks highlights Zoetis as likely to beat upcoming earnings estimates and flags it as a momentum stock — positive near‑term catalyst if results meet expectations. Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy?
• Neutral Sentiment: Coverage pieces note the stock’s year‑to‑date underperformance versus the broader market, though analysts remain cautiously bullish — indicating upside is dependent on execution rather than sentiment alone. Do Wall Street Analysts Like Zoetis Stock?
• Neutral Sentiment: Market calendars note Zoetis is projected to report quarterly results this week — an event that could be a catalyst either way depending on beats or guidance. Zoetis (ZTS) Projected to Post Quarterly Earnings on Thursday
• Negative Sentiment: A valuation/analysis piece cautions that Zoetis’ 2026 outlook is tempered by softer pet clinic visits and increased regulatory scrutiny, which could pressure revenue growth and multiples if trends persist. Zoetis (ZTS) Valuation Check As 2026 Outlook Is Tempered On Softer Pet Visits And Regulatory Scrutiny

Zoetis Price Performance

Shares of Zoetis stock opened at $127.40 on Friday. The company has a market capitalization of $56.14 billion, a price-to-earnings ratio of 21.45, a PEG ratio of 2.20 and a beta of 0.96. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The stock’s 50-day simple moving average is $123.96 and its 200-day simple moving average is $136.31. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.00.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.69%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.